KR101664518B1 - 신경손상을 치료하기 위한 다중불포화 지방산(ｐｕｆａｓ)의 용도 - Google Patents

신경손상을 치료하기 위한 다중불포화 지방산(ｐｕｆａｓ)의 용도 Download PDF

Info

Publication number
KR101664518B1
KR101664518B1 KR1020117028669A KR20117028669A KR101664518B1 KR 101664518 B1 KR101664518 B1 KR 101664518B1 KR 1020117028669 A KR1020117028669 A KR 1020117028669A KR 20117028669 A KR20117028669 A KR 20117028669A KR 101664518 B1 KR101664518 B1 KR 101664518B1
Authority
KR
South Korea
Prior art keywords
cis
group
trans
formula
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117028669A
Other languages
English (en)
Korean (ko)
Other versions
KR20120023729A (ko
Inventor
아담 켈리허
노만 카메론
앵거스 모리슨
필 놀즈
Original Assignee
이쿠아텍 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이쿠아텍 리미티드 filed Critical 이쿠아텍 리미티드
Publication of KR20120023729A publication Critical patent/KR20120023729A/ko
Application granted granted Critical
Publication of KR101664518B1 publication Critical patent/KR101664518B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020117028669A 2009-05-01 2010-04-22 신경손상을 치료하기 위한 다중불포화 지방산(ｐｕｆａｓ)의 용도 Expired - Fee Related KR101664518B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0907601.9 2009-05-01
GBGB0907601.9A GB0907601D0 (en) 2009-05-01 2009-05-01 Novel methods
PCT/GB2010/000817 WO2010125330A1 (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage

Publications (2)

Publication Number Publication Date
KR20120023729A KR20120023729A (ko) 2012-03-13
KR101664518B1 true KR101664518B1 (ko) 2016-10-11

Family

ID=40792178

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117028669A Expired - Fee Related KR101664518B1 (ko) 2009-05-01 2010-04-22 신경손상을 치료하기 위한 다중불포화 지방산(ｐｕｆａｓ)의 용도

Country Status (14)

Country Link
US (1) US20120122982A1 (enExample)
EP (1) EP2424519A1 (enExample)
JP (1) JP5608220B2 (enExample)
KR (1) KR101664518B1 (enExample)
CN (1) CN102448453B (enExample)
AU (1) AU2010243368C1 (enExample)
BR (1) BRPI1009922A2 (enExample)
CA (1) CA2762009C (enExample)
GB (1) GB0907601D0 (enExample)
MX (1) MX2011011615A (enExample)
NZ (1) NZ596674A (enExample)
SG (1) SG175848A1 (enExample)
WO (1) WO2010125330A1 (enExample)
ZA (1) ZA201108571B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2015071766A1 (en) * 2013-11-15 2015-05-21 Dignity Sciences Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006137435A1 (ja) * 2005-06-22 2006-12-28 National University Corporation Gunma University Gタンパク質共役型受容体g2aの作動薬、及びg2a活性調節薬のスクリーニング方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE10940T1 (de) * 1981-05-12 1985-01-15 Imperial Chemical Industries Plc Pyrrolderivate.
US4532254A (en) * 1983-03-17 1985-07-30 Kaken Pharmaceutical Co., Ltd. Inhibitor of aldose reductase
KR910005856B1 (ko) * 1987-09-16 1991-08-05 다이호야꾸힝고오교가부시끼가이샤 티에노피리미딘 유도체
DE69433713T2 (de) * 1993-06-09 2005-04-07 Martek Biosciences Corp. Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
US7015249B1 (en) * 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
US6107349A (en) * 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
GB9827391D0 (en) * 1998-12-11 1999-02-03 Fundation O N C F Aldose reductase inhibitors and pharmaceutical compositions
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
CZ20023562A3 (cs) * 2000-04-28 2003-03-12 Sankyo Company, Limited PPAR gama modulátory
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
AU2002304931A1 (en) * 2001-06-08 2002-12-23 University Of British Columbia Methods for treating disorders of the nervous and reproductive systems
CA2480429C (en) * 2002-03-25 2008-09-16 Biosynergen, Inc. Novel therapeutical use of agonist ligands specific to g2a receptor
JP5366211B2 (ja) * 2007-12-18 2013-12-11 国立大学法人富山大学 アルドース還元酵素阻害活性を有する縮合三環化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006137435A1 (ja) * 2005-06-22 2006-12-28 National University Corporation Gunma University Gタンパク質共役型受容体g2aの作動薬、及びg2a活性調節薬のスクリーニング方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Diabetic neuropathy-a review, Nature Clinical Practice Neurology, 3, 331-340(2007.)*

Also Published As

Publication number Publication date
NZ596674A (en) 2013-09-27
EP2424519A1 (en) 2012-03-07
AU2010243368B2 (en) 2013-10-24
AU2010243368C1 (en) 2014-04-03
WO2010125330A1 (en) 2010-11-04
KR20120023729A (ko) 2012-03-13
AU2010243368A1 (en) 2011-12-15
SG175848A1 (en) 2011-12-29
CA2762009C (en) 2016-11-22
CN102448453A (zh) 2012-05-09
BRPI1009922A2 (pt) 2016-03-15
US20120122982A1 (en) 2012-05-17
MX2011011615A (es) 2012-01-27
CN102448453B (zh) 2016-07-06
JP2012525362A (ja) 2012-10-22
ZA201108571B (en) 2013-01-30
CA2762009A1 (en) 2010-11-04
JP5608220B2 (ja) 2014-10-15
GB0907601D0 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
DE69616376T2 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
JP2001523732A (ja) クロザピンと脂肪酸の共有複合体および精神分裂病の処置のためのその使用
US10888552B2 (en) Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability
KR101664518B1 (ko) 신경손상을 치료하기 위한 다중불포화 지방산(ｐｕｆａｓ)의 용도
KR101898358B1 (ko) 신경계 손상을 수반하는 질병을 치료하기 위한 오메가 3 지방산 조성물
US5516801A (en) Fatty acid treatment for ectopic calcium deposition
KR101233711B1 (ko) 항염증제로서 유용한 알파-아미노아미드 유도체
CN114344313A (zh) 用于预防或治疗神经系统退行性疾病的白桦脂酸衍生物
JP4303474B2 (ja) 医薬活性のある化合物及び使用方法
JP2021505668A (ja) 併用療法（睡眠障害およびｃｎｓ障害）において使用するためのｎｍｄａ受容体モジュレーター（ラパスチネル）の組合せ
KR102721799B1 (ko) 신규한 카나비디올 유도체, 이의 제조 방법 및 이를 포함하는 파킨슨병의 예방 또는 치료용 조성물
KR20250071888A (ko) 신규한 카나비디올 유도체, 이의 제조방법 및 이를 포함하는 뇌전증 치료용 약학 조성물
US8975298B2 (en) Therapeutic agent for pain
TWI533869B (zh) 蒽醌［２，１－ｃ］［１，２，５］噻二唑－６，１１－二酮化合物緩解疼痛的應用
JP4366533B2 (ja) 睡眠障害の治療剤
JP7257091B2 (ja) 認知症の治療及び予防薬
AU773733B2 (en) Methods for the treatment and prevention of neurodegenerative conditions
TWI533871B (zh) 萘并［２，３－ｆ］喹喔啉－７，１２－二酮化合物緩解疼痛的應用
JP6216913B1 (ja) 医薬組成物
Jang et al. Effects of propofol administration rates on cardiopulmonary function and anaesthetic depth during anaesthetic induction in rats
PT2809320T (pt) (1r,4r)-6'-fluoro-(n-metil ou n,n-dimetil)-4-fenil-4',9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano-[3,4,b]indol]-4-amina para o tratamento de fibromialgia e de síndrome de fadiga crónica

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191005

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191005